Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neuroleptic Treatment”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Study completedNCT00334035
What this trial is testing

Antipsychotic Therapy and First Episode

Who this might be right for
Schizophrenia
The University of Hong Kong 169
Testing effectiveness (Phase 2)Ended earlyNCT00686699
What this trial is testing

Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)

Who this might be right for
Akathisia, Drug-InducedDyskinesia, Drug-InducedParkinsonian Disorders
Merck Sharp & Dohme LLC 11
Large-scale testing (Phase 3)Study completedNCT01143077
What this trial is testing

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

Who this might be right for
SchizophreniaSchizoaffective Disorder
Sumitomo Pharma America, Inc. 244
Post-approval studies (Phase 4)Ended earlyNCT00508157
What this trial is testing

Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome

Who this might be right for
Metabolic SyndromeSchizophrenia
Bristol-Myers Squibb 125
Large-scale testing (Phase 3)UnknownNCT01280305
What this trial is testing

Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder

Who this might be right for
SchizophreniaSchizoaffective Disorder
Sheba Medical Center 200
Large-scale testing (Phase 3)Study completedNCT00649844
What this trial is testing

A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs

Who this might be right for
Schizophrenia
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 147
Not applicableStudy completedNCT00222807
What this trial is testing

Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus

Who this might be right for
SchizophreniaSchizoaffective DisorderDelusional Disorder
University of Pittsburgh 200
Not applicableStudy completedNCT01222494
What this trial is testing

Healthy Bodies, Healthy Kids

Who this might be right for
Child Mental DisordersObesityMetabolic Syndrome
Washington University School of Medicine 47
Not applicableUnknownNCT01831986
What this trial is testing

Pregnenolone and L-theanine Augmentation in the Treatment for Schizophrenia and Schizoaffective Disorders

Who this might be right for
SchizophreniaSchizoaffective Disorder
Sha'ar Menashe Mental Health Center 60
Not applicableStudy completedNCT01234454
What this trial is testing

Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI

Who this might be right for
Schizophrenia
University of North Carolina, Chapel Hill 34
Post-approval studies (Phase 4)WithdrawnNCT01193166
What this trial is testing

Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital

Who this might be right for
Schizophrenia
Ortho-McNeil Janssen Scientific Affairs, LLC
Large-scale testing (Phase 3)Study completedNCT00083668
What this trial is testing

Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia

Who this might be right for
Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 619
Large-scale testing (Phase 3)Study completedNCT01421342
What this trial is testing

VA Augmentation and Switching Treatments for Improving Depression Outcomes

Who this might be right for
Major Depressive Disorder
VA Office of Research and Development 1,522
Not applicableUnknownNCT03434210
What this trial is testing

The Effect of a Community-based LAT-treated Management Model on the Violence Risk of Patients With Schizophrenia

Who this might be right for
Schizophrenia
Yi Li MD, PhD 110
Large-scale testing (Phase 3)Study completedNCT00167154
What this trial is testing

Risperidone and Suicidality in Major Depressive Disorder

Who this might be right for
Depression
University of Alabama at Birmingham 30
Not applicableStudy completedNCT00696813
What this trial is testing

Observational Study to Assess Outcomes During Antipsychotic Treatment With Paliperidone ER or Other Oral Antipsychotics

Who this might be right for
Schizophrenia
Janssen-Cilag International NV 3,064
Not applicableStudy completedNCT01804582
What this trial is testing

The Family VOICE Study

Who this might be right for
AutismAggressionBipolar Disorder+1 more
University of Maryland, Baltimore 350
Early research (Phase 1)Study completedNCT00791622
What this trial is testing

QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine

Who this might be right for
SchizophreniaSchizoaffective Disorder
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 110
Large-scale testing (Phase 3)Study completedNCT01994109
What this trial is testing

Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects

Who this might be right for
Sialorrhea
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC 187
Large-scale testing (Phase 3)Study completedNCT00518323
What this trial is testing

A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

Who this might be right for
Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 201
Next Page